Royalty Pharma plc (RPRX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Royalty Pharma reported revenue of $2.38B, up 5.1% from $2.26B the year before. Net income was $770.9M (a 32.4% net margin), or $1.78 per diluted share. Gross margin was 65.6% and operating margin was 65.6%. Operating activities generated $2.49B of cash. At fiscal year end, Royalty Pharma held $19.62B in total assets against $9.91B in total liabilities, including $618.7M of cash and equivalents.
Open the full interactive Royalty Pharma financials → Quarterly statements, key ratios, valuation history and price charts.
Royalty Pharma Key Stats
| Share Price | $56.57 |
|---|---|
| Market Cap | $31.50B |
| P/E Ratio | 31.8 |
| Revenue YoY Growth | +5.1% |
| 52-Week Range | $34.77 – $63.96 |
| Shares Outstanding | 445.1 million (basic, 2026 Q2) |
Royalty Pharma Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $2.12B | $2.29B | $2.24B | $2.35B | $2.26B | $2.38B |
| Cost of Goods Sold | $527.0M | $858.7M | $1.93B | $862.4M | $971.1M | $818.7M |
| Gross Profit | $1.60B | $1.43B | $307.1M | $1.49B | $1.29B | $1.56B |
| Operating Income | $1.60B | $1.43B | $307.1M | $1.49B | $1.29B | $1.56B |
| Pre-Tax Income | $1.70B | $1.24B | $230.1M | $1.70B | $1.33B | $1.32B |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $975.0M | $619.7M | $42.8M | $1.13B | $859.0M | $770.9M |
| Diluted EPS | $1.32 | $1.49 | $0.10 | $2.53 | $1.91 | $1.78 |
Royalty Pharma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $609.3M | $622.0M | $630.6M | $674.1M |
| Net Income | $288.2M | $214.2M | $294.7M | $17.9M |
| Diluted EPS | $0.67 | $0.38 | $0.67 | $0.04 |
Royalty Pharma Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.01B | $1.54B | $1.71B | $477.0M | $929.0M | $618.7M |
| Current Assets | $2.70B | $2.88B | $2.55B | $1.27B | $1.80B | $1.53B |
| Total Assets | $16.02B | $17.52B | $16.81B | $16.38B | $18.22B | $19.62B |
| Current Liabilities | $307.9M | $171.2M | $1.17B | $161.4M | $1.25B | $636.2M |
| Total Long-Term Debt | $5.82B | $7.10B | $7.12B | $6.14B | $7.61B | $8.95B |
| Total Liabilities | $6.12B | $7.27B | $7.29B | $6.30B | $7.88B | $9.91B |
| Shareholders' Equity | $9.90B | $10.25B | $9.53B | $10.08B | $10.34B | $9.71B |
Royalty Pharma Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $2.03B | $2.02B | $2.14B | $2.99B | $2.77B | $2.49B |
| Cash From Investing | -$2.76B | -$1.87B | -$1.03B | -$2.07B | -$2.68B | -$1.61B |
| Cash From Financing | $1.49B | $385.1M | -$944.9M | -$2.15B | $361.1M | -$1.19B |
Figures from Royalty Pharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Royalty Pharma financials page for every line item.
Royalty Pharma Company Profile
| Ticker | RPRX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | New York, New York |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001802768 |
Frequently Asked Questions
What was Royalty Pharma's revenue in fiscal 2025?
Royalty Pharma (RPRX) reported revenue of $2.38B for fiscal 2025.
What is Royalty Pharma's annual revenue history?
Royalty Pharma's annual revenue by fiscal year: 2020: $2.12B; 2021: $2.29B; 2022: $2.24B; 2023: $2.35B; 2024: $2.26B; 2025: $2.38B.
What was Royalty Pharma's net income in fiscal 2025?
Royalty Pharma reported net income of $770.9M for fiscal 2025.
What was Royalty Pharma's earnings per share (EPS) in fiscal 2025?
Royalty Pharma's diluted EPS was $1.78 for fiscal 2025 (adjusted for any later stock splits).
What was Royalty Pharma's revenue last quarter?
In its most recent reported quarter (2026 Q2), Royalty Pharma reported revenue of $674.1M.
How much debt does Royalty Pharma have?
Royalty Pharma reported $8.95B of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Royalty Pharma are outstanding?
Royalty Pharma reported a weighted average of 445.1 million basic shares outstanding in 2026 Q2.
What is Royalty Pharma's market cap?
Based on its latest closing price, Royalty Pharma (RPRX) has a market capitalization of about $31.50B.
When does Royalty Pharma's fiscal year end?
Royalty Pharma's fiscal year end, as registered with the SEC, is December 31.
Where is Royalty Pharma headquartered?
Royalty Pharma lists its business address in New York, New York in its SEC filings.